52.98
1.85 (3.62%)
Penutupan Terdahulu | 51.13 |
Buka | 51.30 |
Jumlah Dagangan | 83,620 |
Purata Dagangan (3B) | 439,877 |
Modal Pasaran | 1,834,925,184 |
Harga / Buku (P/B) | 2.68 |
Julat 52 Minggu | |
Tarikh Pendapatan | 6 Aug 2025 - 11 Aug 2025 |
EPS Cair (TTM) | -3.89 |
Jumlah Hutang/Ekuiti (D/E MRQ) | 4.64% |
Nisbah Semasa (MRQ) | 37.65 |
Aliran Tunai Operasi (OCF TTM) | -101.70 M |
Aliran Tunai Bebas Leveraj (LFCF TTM) | -66.74 M |
Pulangan Atas Aset (ROA TTM) | -16.25% |
Pulangan Atas Ekuiti (ROE TTM) | -23.33% |
Arah Aliran Pasaran
Jangka Pendek | Jangka Sederhana | ||
Industri | Biotechnology (US) | Menurun | Menurun |
Biotechnology (Global) | Menurun | Menurun | |
Stok | Disc Medicine, Inc. | Bercampur | Menaik |
AISkor Stockmoo
Konsensus Penganalisis | 4.0 |
Aktiviti Orang Dalam | NA |
Volatiliti Harga | -2.0 |
Purata Bergerak Teknikal | -1.0 |
Osilator Teknikal | 2.0 |
Purata | 0.75 |
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company’s preclinical programs include DISC-0998. |
|
Sektor | Healthcare |
Industri | Biotechnology |
Gaya Pelaburan | Small Core |
% Dimiliki oleh Orang Dalam | 10.57% |
% Dimiliki oleh Institusi | 98.87% |
Pemilikan
Nama | Tarikh | Syer Dipegang |
---|---|---|
Atlas Venture Life Science Advisors, Llc | 31 Mar 2025 | 2,384,456 |
Siren, L.L.C. | 31 Mar 2025 | 1,071,865 |
Julat 52 Minggu | ||
Julat Harga Sasaran | ||
Tinggi | 120.00 (BMO Capital, 126.50%) | Beli |
Median | 118.00 (122.73%) | |
Rendah | 89.00 (Raymond James, 67.99%) | Beli |
Purata | 109.00 (105.74%) | |
Jumlah | 3 Beli | |
Harga Purata @ Panggilan | 50.15 |
Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
---|---|---|---|---|
HC Wainwright & Co. | 03 Jul 2025 | 118.00 (122.73%) | Beli | 52.98 |
17 Jun 2025 | 118.00 (122.73%) | Beli | 50.05 | |
Raymond James | 11 Jun 2025 | 89.00 (67.99%) | Beli | 50.86 |
BMO Capital | 12 May 2025 | 120.00 (126.50%) | Beli | 46.61 |
Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
---|---|---|---|---|
SAVAGE WILLIAM JACOB | - | - | 0 | 0 |
Jumlah Keseluruhan Kuantiti Bersih | 0 | |||
Jumlah Keseluruhan Nilai Bersih ($) | 0 | |||
Purata Pembelian Keseluruhan ($) | - | |||
Purata Jualan Keseluruhan ($) | - |
Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
---|---|---|---|---|---|---|
SAVAGE WILLIAM JACOB | Pegawai | 27 Jun 2025 | Pelaksanaan pilihan | 32,070 | - | - |
Tarikh | Jenis | Butiran |
---|---|---|
12 Jun 2025 | Pengumuman | Disc Medicine Presents Positive Clinical Data Updates Across Portfolio at the European Hematology Association (EHA) 2025 Annual Congress |
28 May 2025 | Pengumuman | Disc Medicine to Participate in Upcoming Investor Conferences |
14 May 2025 | Pengumuman | Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2025 Congress |
13 May 2025 | Pengumuman | Disc Medicine to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference |
07 May 2025 | Pengumuman | Disc Medicine Reports First Quarter 2025 Financial Results and Provides Business Update |
29 Apr 2025 | Pengumuman | Disc Medicine to Host Webinar with Key Opinion Leaders on Anemia of Myelofibrosis (MF) |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
Keuntungan Nyata | - |
Keuntungan Tidak Nyata | - |
Dividen Diterima 2025 | - |
Jumlah Untung | - |
Pulangan Purata | - |
Kuantiti (Beli) | - |
Purata Harga (Beli) | - |
Kuantiti (Jual) | - |
Purata Harga (Jual) | - |